Assistant Professor UCSD | UCSD AHFTC ‘26 | UC Davis Cardiology '25 | UCLA Internal Medicine '22 | Tulane MD/MBA '19 | Believer in Heart Success |

San Diego, CA
Joined October 2020
A 🧵on STRONG-HF 💪🏾🫀 ⭐️The first randomized trial to show the immense benefits of a comprehensive high-intensity med-titration program with #HF GDMT ❓How did the investigators achieve an 8.1% ARR in HFH/mortality at 6 months❓ Let’s see what we can learn 👇🏾🧵
1
62
3
207
Very excited to be here!
Welcoming Neal Dixit, MD (@NealDixit) to the Advanced Heart Failure and Transplant Cardiology faculty! @UCSDCardFellows @UCSDHealthSci @ucsdim
2
2
32
2,994
Neal Dixit, MD retweeted
Won’t 💊 cost too much? With generic pricing: $3.5 billion a year Optimal implementation in eligible patients with HF, CKD & T2DM is projected to: 🏥 Reduce billions in CV/HF 🏨s 🫘 Avoid dialysis costs in CKD Not prescribing SGLT2i way more costly #SGLT2i #ValueBasedCare
1
1
2
437
Excited to share our review on predicting sudden cardiac death in HFrEF led by outstanding med student Norayr Mkrtchyan! It's a comprehensive look at the risk factors associated with sudden death in this population @AntoinetteBirs @AHajduczok link.springer.com/article/10…
1
3
1
10
1,952
Neal Dixit, MD retweeted
Is finerenone ready for primetime in heart failure? We argue that the data suggest not yet. @NealDixit @cardiologyUc #AHAJournals ahajrnls.org/3Gn7QkZ
1
1
3
646
Is it primetime for finerenone in HF? Would love to hear why or why not? Here is our perspective 👇🏾 ahajournals.org/doi/10.1161/…
1
2
8
1,615
Congrats @NealDixit !!! Can’t wait for you to join the awesome team at @UCSDCardiology ❤️
Ecstatic to share that I will be joining @HowieTranMD and the team at @UCSDCardFellows for Advanced Heart Failure and Transplant Cardiology Fellowship!
2
9
1,642
Ecstatic to share that I will be joining @HowieTranMD and the team at @UCSDCardFellows for Advanced Heart Failure and Transplant Cardiology Fellowship!
3
1
1
39
4,613
Is Finerenone just an expensive spironolactone? "A RCT of nonsteroidal versus steroidal MRAs is desperately needed in the HF population" Thanks for your thoughtful Editorial, @NealDixit and Saul Schaefer! @dgfn_ev @YoungDgk @MarcusSaemann @hswapnil ahajournals.org/doi/10.1161/…
7
1
27
4,158
Neal Dixit, MD retweeted
Costs? Intolerance? Inertia? Other? Primary reason for gaps in #GDMTworks endlessly debated. 🤔What if we had US physicians audit their own patient charts & report *WHY* they didn’t prescribe #GDMT for #HFrEF in each case? 🚨 Results in @JACCJournals jacc.org/doi/epdf/10.1016/j.…
5
36
3
81
21,281
Will DANCAVAS be the most important screening trial in the last 50 years? Interested to hear opinions! Read our commentary 👇🏾 sciencedirect.com/science/ar…
1
2
16
1,080
Neal Dixit, MD retweeted
1
13
31
2,594
In #JACCHF @JACCJournals: cost effectiveness of medical tx for #HFmrEF & #HFpEF *At current cost, MRA high value, SGLT2i intermediate value, & ARNI low value *If generic, all are high value 🛑Need equitable access to meds for all!🛑 jacc.org/doi/10.1016/j.jchf.… @gcfmd @NealDixit
2
11
28
4,579
Neal Dixit, MD retweeted
Generic priced options are here or just around the corner Cost-Effectiveness of Medical Therapy for Heart Failure With Mildly Reduced and Preserved Ejection Fraction | JACC: Heart Failure jacc.org/doi/10.1016/j.jchf.… @NealDixit @JACCJournals
1
7
1
28
2,974
Once again, nice work @NealDixit . I often start SGLT2- and MRA first as easy to get to targeted dose fast. Now its cost effective too!
What is a cost-effective GDMT strategy for HFmrEF/HFpEF? We built a model w/ clinical trial data (TOPCAT, PARAGON-HF, EMPEROR/DELIVER) and simulated outcomes w/ regimens of MRA/SGLT2i/ARNi. Best 💊 combo? MRA + SGLT2i ARNi ⬇️ value at current 💵 Treat HF with urgency!
2
5
1,136
What is a cost-effective GDMT strategy for HFmrEF/HFpEF? We built a model w/ clinical trial data (TOPCAT, PARAGON-HF, EMPEROR/DELIVER) and simulated outcomes w/ regimens of MRA/SGLT2i/ARNi. Best 💊 combo? MRA + SGLT2i ARNi ⬇️ value at current 💵 Treat HF with urgency!
2
32
4
84
14,464
Neal Dixit, MD retweeted
💶💵 Cost-Effectiveness of Medical Therapy for HFmrEF/HFpEF 💊MRA 💊💊MRA + SGLT2i 💊💊💊 MRA + SGLT2i+ARNI ↗️ in life years of HFmrEF/HFpEF👥 💊1.04/0.99 2️⃣💊1.58/1.54 3️⃣💊1.80/1.77 💊MRA therapy ICERs of $10,000 per r QALY in both subgroups 💊💊ICER $113,000 per QALY in the HFmrEF subgroup and $141,000 in the HFpEF subgroup. 💊💊💊ICERs>$250,000 per QALY in both subgroups. 💡👥 with HFmrEF/HFpEF ↗️ use of MRA and SGLT2i therapies should be encouraged Via @JACCJournals @mvaduganathan @gcfmd @NealDixit &cia 📁 jacc.org/doi/10.1016/j.jchf.… – at Denia, Spain
45
2
96
9,104
Neal Dixit, MD retweeted
Cost effectiveness analysis of 💊 Rx in HFmrEF/HFpEF Timing of generic pricing is 🔑 Cost-Effectiveness of Medical Therapy for Heart Failure With Mildly Re... sciencedirect.com/science/ar… @boback @NealDixit @JACCJournals
9
33
4,216